U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C22H32N2O6.2ClH
Molecular Weight 493.421
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEXOPRENALINE DIHYDROCHLORIDE

SMILES

Cl.Cl.OC(CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1)C2=CC=C(O)C(O)=C2

InChI

InChIKey=LECFJMMCVCBLPN-UHFFFAOYSA-N
InChI=1S/C22H32N2O6.2ClH/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16;;/h5-8,11-12,21-30H,1-4,9-10,13-14H2;2*1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C22H32N2O6
Molecular Weight 420.4993
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html

Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
Unknown

Approved Use

Unknown
Primary
Approved
8583
Unknown

Approved Use

Unknown
Primary
Approved
8583
Unknown

Approved Use

Unknown
Preventing
Approved
8583
GYNIPRAL

Approved Use

Gynipral prevents threatened abortion with premature labour.
Doses

Doses

DosePopulationAdverse events​
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
Other AEs: Tachycardia, Palpitation...
Other AEs:
Tachycardia
Palpitation
Tremor muscle
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
1 mg 4 times / day multiple, intravenous
Recommended
Dose: 1 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/195789/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/195789/
Other AEs: Palpitations, Tremor...
Other AEs:
Palpitations (11%)
Tremor (9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/195789/
500 ug 6 times / day multiple, respiratory
Recommended
Dose: 500 ug, 6 times / day
Route: respiratory
Route: multiple
Dose: 500 ug, 6 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
Other AEs: Tachycardia, Palpitation...
Other AEs:
Tachycardia
Palpitation
Tremor muscle
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
AEs

AEs

AESignificanceDosePopulation
Palpitation
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
Tachycardia
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
Tremor muscle
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
Palpitations 11%
1 mg 4 times / day multiple, intravenous
Recommended
Dose: 1 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/195789/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/195789/
Tremor 9%
1 mg 4 times / day multiple, intravenous
Recommended
Dose: 1 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/195789/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/195789/
Palpitation
500 ug 6 times / day multiple, respiratory
Recommended
Dose: 500 ug, 6 times / day
Route: respiratory
Route: multiple
Dose: 500 ug, 6 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
Tachycardia
500 ug 6 times / day multiple, respiratory
Recommended
Dose: 500 ug, 6 times / day
Route: respiratory
Route: multiple
Dose: 500 ug, 6 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
Tremor muscle
500 ug 6 times / day multiple, respiratory
Recommended
Dose: 500 ug, 6 times / day
Route: respiratory
Route: multiple
Dose: 500 ug, 6 times / day
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic
PubMed

PubMed

TitleDatePubMed
Management of foetal asphyxia by intrauterine foetal resuscitation.
2010-09
Dependence of the lymphocyte proliferative response on the endogenous cortisol level and sensitivity to β-adrenergic regulation in vitro in the early period of penetrating eye injury.
2010-05-17
Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation.
2009-06-19
Treatment of pregnant women with a betamimetic and verapamil increases the micronuclei frequency in umbilical cord blood lymphocytes.
2008-08
Flow injection potentiometric assay of hexoprenaline in its pure state, pharmaceutical preparations, and biological samples.
2008
Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor.
2005-12
Circulatory corticotropin-releasing hormone mRNA concentrations are increased in women with preterm delivery but not in those who respond to tocolytic treatment.
2005-03
Betamimetics for inhibiting preterm labour.
2004-10-18
Beta 2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats.
2004-09
A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation.
2004-04
[Comparison of the cost of treatment of premature labor with atosiban or beta-sympathomimetics from the perspective of the health care payer--a pharmacoeconomic model].
2004-03
The effects of fetal breathing movements on the utero-fetal-placental circulation.
2001-01
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.
2001
A comparison of the relative toxicities of beta-sympathomimetic tocolytic agents.
1985-10
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison].
1983-03
Hexoprenaline: a review of its pharmacological properties and therapeutic efficacy with particular reference to asthma.
1977-07

Sample Use Guides

In Vivo Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/195789
Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:43:50 GMT 2025
Edited
by admin
on Mon Mar 31 21:43:50 GMT 2025
Record UNII
97TDI0239I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEXOPRENALINE HYDROCHLORIDE
WHO-DD  
Preferred Name English
HEXOPRENALINE DIHYDROCHLORIDE
MI  
Common Name English
Hexoprenaline hydrochloride [WHO-DD]
Common Name English
HEXOPRENALINE HCL
Common Name English
HEXOPRENALINE DIHYDROCHLORIDE [MI]
Common Name English
BENZYL ALCOHOL, .ALPHA.,.ALPHA.'-(HEXAMETHYLENEBIS(IMINOMETHYLENE))BIS(3,4-DIHYDROXY-, DIHYDROCHLORIDE
Common Name English
Code System Code Type Description
SMS_ID
100000128147
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY
CAS
4323-43-7
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY
PUBCHEM
20321
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY
EPA CompTox
DTXSID60962973
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY
ECHA (EC/EINECS)
224-354-2
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY
FDA UNII
97TDI0239I
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY
EVMPD
SUB34902
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY
MERCK INDEX
m6013
Created by admin on Mon Mar 31 21:43:50 GMT 2025 , Edited by admin on Mon Mar 31 21:43:50 GMT 2025
PRIMARY Merck Index
Related Record Type Details
Structure of HEXOPRENALINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of HEXOPRENALINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966